First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.

Core Viewpoint - Novo Nordisk has launched the first-ever GLP-1 oral pill for weight loss in the U.S., marking a significant advancement in obesity treatment [1][2]. Pricing and Accessibility - The cash prices for the Wegovy pill range from $149 to $299 per month, depending on the dosage, which aims to address affordability issues associated with existing weekly injection treatments [2][4]. - The starting dose of 1.5 milligrams is available at over 70,000 U.S. pharmacies and select telehealth providers, with higher doses expected to be available shortly [3]. - Patients with insurance can access the drug for as low as $25 per month, while cash-paying patients can also purchase it through a deal with TrumpRx for $149 per month [4][5]. Market Potential - The GLP-1 market is projected to be worth approximately $100 billion by the 2030s, with oral drugs potentially capturing a 24% market share, equating to around $22 billion [7]. - Novo Nordisk's launch gives it a competitive edge as it awaits FDA approval for a rival pill from Eli Lilly later this year [8]. Clinical Efficacy - In a phase three trial, the highest dose of the oral semaglutide led to an average weight loss of 16.6% after 64 weeks, with a 13.6% weight loss observed across all participants [11]. - The Wegovy pill is reported to be slightly more effective than Eli Lilly's experimental oral drug, which does not impose dietary restrictions [12]. Regulatory Approval - The FDA approved the Wegovy pill for weight loss and for reducing the risk of major cardiovascular events in adults with obesity and established cardiovascular disease [8][9].